Premium
Transforming growth factor‐β1 enhances the antifibrinolytic and prothrombotic state of growing endothelial cells in a cell cycle‐specific manner
Author(s) -
Stoldt Volker R.,
Schnorr Oliver,
SchulzeOsthoff Klaus,
Scharf Ruediger E.
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.04-3032fje
Subject(s) - thrombomodulin , cell cycle , transforming growth factor , umbilical vein , microbiology and biotechnology , endothelial stem cell , chemistry , protein c , human umbilical vein endothelial cell , cell , antithrombotic , biology , medicine , thrombin , immunology , biochemistry , platelet , in vitro
Cell cycle-dependent modulation of protein expression may influence the balance of antithrombotic and prothrombotic properties of endothelial cells. In the present study, we examined the regulation of prothrombotic and antithrombotic molecules by transforming growth factor-beta1 (TGF-beta1) during distinct phases of the cell cycle in human umbilical vein endothelial cells. In the absence of TGF-beta1, the expression of thrombomodulin, the plasminogen activators u-PA and t-PA, and their inhibitor PAI-1 was significantly increased in the S/G2 compared to the G1 phase. Treatment of endothelial cells with TGF-beta1, however, resulted in elevated expression of PAI-1 specifically in the S/G2 phase, while t-PA and u-PA increased to the same extent in both the G1 and S/G2 phase. These findings demonstrate that the expression of a subset of hemostatically relevant proteins is regulated during endothelial cell cycle and that TGF-beta1 can differentially modulate cell cycle-controlled protein expression.